Safety, Pharmacokinetics, and Pharmacodynamics of Etrasimod: Single and Multiple Ascending Dose Studies in Healthy Adults

• Published in: Clinical pharmacology in drug development Vol. 13; no. 5; pp. 534 - 548
• Main Authors: Lee, Caroline A., Schreiber, Stefan, Bressler, Brian, Adams, John W., Oh, Dooman Alexander, Tang, Yong Q., Zhang, Jinkun, Komori, Heather Kiyomi, Grundy, John S.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.05.2024
• Subjects: etrasimod; inflammatory disease; lymphocyte; Lymphocytes; Pharmacodynamics; Pharmacokinetics; sphingosine 1‐phosphate receptor; inflammatory disease; pharmacokinetics; sphingosine 1-phosphate receptor; etrasimod; lymphocyte

Etrasimod is an investigational, once‐daily, oral, selective sphingosine 1‐phosphate receptor 1,4,5 modulator in development for immune‐mediated inflammatory diseases (IMIDs). Here, we report the human safety, pharmacokinetics, and pharmacodynamics of etrasimod obtained from both a single ascending...